5th Annual Partnerships in Clinical Trials Congress (PCT) and Exhibition

Posted:
15
August 2006

Win a VIP invite to the Partnerships in Clinical Trials congress (PCT), Belgium including:

  • Delegate pass for the duration of the event
  • Travel and accommodation costs

Richmond Pharmacology will be exhibiting at this years PCT congress 13th-15th November 2006, Brussels Expo, Belgium www.ct-partnerships.com.Managing Director Dr Jorg Taubel of Richmond Pharmacology is on the panel of guest speakers and will be covering the topic:'Effective Partnering between Sponsors & Niche Providers'Examining:

  • What niche providers can deliver that global CROs cannot
  • How do partnerships between smaller sponsors & niche providers benefit both
  • The role niche providers play in global clinical trials

If you are planning to attend the conference then please take a look at our prize draw below:We are running a prize draw to win a VIP invite to the PCT event which includes:

  • Delegate pass for 2 days for 1 guest
  • Travel and accommodation costs for the duration of the event for 1 guest

To attend the conference as a guest of Richmond Pharmacology why not enter the prize draw below to be in with a chance to win.To enter, click here

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more